Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2862 | Performance of WHEELS-I in promoting DASH/SRD adoption Wiki | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
Tens of thousands of Veterans have heart failure with preserved ejection fraction (HFpEF), and suffer poor quality of life, frequent hospitalizations, and high death rates. Older Veterans and those with high blood pressure, obesity, and the metabolic syndrome (abnormal cholesterol and resistance to insulin's effects) are particularly at risk for HFpEF. However, it is not clear why only some Veterans in this risk group eventually develop HFpEF. Extensive information from experimental animal models and some human studies suggests that dietary patterns in vulnerable 'salt-sensitive' people could contribute to the risk for HFpEF. Reducing salt intake and increasing overall dietary quality in at-risk Veterans could prevent heart and blood vessel damage that ultimately leads to HFpEF. Reducing the development of HFpEF, which currently has no definitive treatment, is highly relevant to the VA's mission to emphasize prevention of disease and population health.
Description: Velocity of pulse wave traveling between carotid and femoral artery; validated measure of arterial stiffness
Measure: Carotid-femoral pulse wave velocity Time: Phase 1 of study, change from baseline at the end of week 2 and week 4Description: Left ventricular mass indexed to height
Measure: Left ventricular mass index Time: Phase 2 of study, change from baseline to 6 monthsDescription: Ventricular stiffness k, by Parametrized Diastolic Formalism analysis
Measure: Ventricular stiffness Time: Phase 1 of study, change from baseline at the end of week 2 and week 4Description: Global longitudinal left ventricular strain, a sensitive measure of ventricular systolic function
Measure: Global longitudinal left ventricular strain Time: Phase 1 of study, change from baseline at the end of week 2 and week 4Description: Global left atrial strain, a novel measure of atrial function
Measure: Global left atrial strain Time: Phase 1 of study, change from baseline at the end of week 2 and week 4Description: Velocity of pulse wave traveling between carotid and femoral artery; validated measure of arterial stiffness
Measure: Carotid-femoral pulse wave velocity Time: Phase 2 of study, change from baseline to 6 monthsDescription: Left atrial volume by 3D echocardiography
Measure: Left atrial volume Time: Phase 2 of study, change from baseline to 6 monthsDescription: Change in 24-hour mean of >= 8 mmHg will define the salt-sensitive blood pressure phenotype
Measure: Salt-sensitivity phenotype Time: Phase 1 of study, change from baseline at the end of week 2 and week 4Description: Measure of dietary sodium intake
Measure: 24-hour urinary sodium excretion Time: Phase 2 of study, change from baseline to 6 monthsDescription: Sodium-restricted DASH diet score on Food Frequency Questionnaire, measured by complete or partial adherence to 9 dietary domains
Measure: Sodium-restricted DASH diet adherence Time: Phase 2 of study, change from baseline to 6 monthsDescription: Analysis of 3-day food diaries by a Registered Dietitian, utilizing the Nutrition Data System for Research
Measure: Sodium-restricted DASH diet adherence Time: Phase 2 of study, months 1 and 6Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports